An
Contouring
Pancoast tumor
QA
Quality assurance
Target volumes
Thoracic
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
06
12
2018
revised:
03
01
2019
accepted:
04
01
2019
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
Target delineation variability is a significant technical impediment in multi-institutional trials which employ intensity modulated radiotherapy (IMRT), as there is a real potential for clinically meaningful variances that can impact the outcomes in clinical trials. The goal of this study is to determine the variability of target delineation among participants from different institutions as part of Southwest Oncology Group (SWOG) Radiotherapy Committee's multi-institutional CT simulation scans were acquired from four patients with Pancoast tumor. Two patients had simulation 4D-CT and FDG-FDG PET-CT while two patients had 3D-CT and FDG-FDG PET-CT. Seventeen SWOG-affiliated physicians independently delineated target volumes defined as gross primary and nodal tumor volumes (GTV_P & GTV_N), clinical target volume (CTV), and planning target volume (PTV).Six board-certified thoracic radiation oncologists were designated as the 'Experts' for this study. Their delineations were used to create a simultaneous truth and performance level estimation (STAPLE) contours using ADMIRE software (Elekta AB, Sweden 2017). Individual participants' contours were then compared with Experts' STAPLE contours. When compared to the Experts' STAPLE, GTV_P had the best agreement among all participants, while GTV_N showed the lowest agreement among all participants. There were no statistically significant differences in all studied parameters for all TVs for cases with 4D-CT versus cases with 3D-CT simulation scans. High degree of inter-observer variation was noted for all target volume except for GTV_P, unveiling potentials for protocol modification for subsequent clinically meaningful improvement in target definition. Various similarity indices exist that can be used to guide multi-institutional radiotherapy delineation QA credentialing.
Identifiants
pubmed: 30775563
doi: 10.1016/j.ctro.2019.01.001
pii: S2405-6308(18)30113-7
pmc: PMC6365802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83-92Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA029511
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097007
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214825
Pays : United States
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180927
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180803
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA225190
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233324
Pays : United States
Organisme : NIDCR NIH HHS
ID : R56 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA154601
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
J Thorac Cardiovasc Surg. 2001 Mar;121(3):472-83
pubmed: 11241082
IEEE Trans Med Imaging. 2004 Jul;23(7):903-21
pubmed: 15250643
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):954-60
pubmed: 15708280
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):435-48
pubmed: 16198064
Strahlenther Onkol. 2006 Aug;182(8):450-7
pubmed: 16896591
Cancer Imaging. 2006 Sep 07;6:116-23
pubmed: 16966067
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Cancer Imaging. 2004 Mar 26;4(2):68-73
pubmed: 18250011
J Thorac Oncol. 2008 Dec;3(12):1433-8
pubmed: 19057269
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30
pubmed: 19117696
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):379-85
pubmed: 19467804
Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6
pubmed: 19699647
Clin Cancer Res. 2009 Sep 15;15(18):5663-70
pubmed: 19723641
J Med Phys. 2008 Oct;33(4):136-40
pubmed: 19893706
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):481-9
pubmed: 20400244
J Thorac Oncol. 2010 Jun;5(6):837-40
pubmed: 20421820
Radiother Oncol. 2010 Dec;97(3):572-8
pubmed: 20708285
J Clin Oncol. 2010 Dec 20;28(36):5301-10
pubmed: 21079134
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e391-8
pubmed: 22284035
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1455-62
pubmed: 22401917
Am J Clin Oncol. 2012 Dec;35(6):612-7
pubmed: 23165357
Sci Transl Med. 2013 Feb 20;5(173):173sr2
pubmed: 23427246
J Natl Cancer Inst. 2013 Mar 20;105(6):387-93
pubmed: 23468460
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
Pract Radiat Oncol. 2013 Jan-Mar;3(1):54-66
pubmed: 24674264
Pract Radiat Oncol. 2013 Jul-Sep;3(3):186-193
pubmed: 24674363
Ann Thorac Surg. 2014 Aug;98(2):402-10
pubmed: 24980603
Radiother Oncol. 2014 Sep;112(3):418-24
pubmed: 24996454
Nucl Med Biol. 2015 Apr;42(4):349-54
pubmed: 25595135
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):911-20
pubmed: 26104943
BMC Med Imaging. 2015 Aug 12;15:29
pubmed: 26263899
Phys Med Biol. 2015 Nov 21;60(22):R323-61
pubmed: 26509844
Rep Pract Oncol Radiother. 2016 Sep-Oct;21(5):427-34
pubmed: 27489512
J Radiat Oncol. 2016 Mar;5(1):55-61
pubmed: 27570583
Clin Oncol (R Coll Radiol). 2018 Apr;30(4):225-232
pubmed: 29397271
Clin Cancer Res. 2018 Aug 1;24(15):3500-3509
pubmed: 29661779
Acta Oncol. 2018 Oct 30;:1-9
pubmed: 30375905
Psychol Rep. 1966 Aug;19(1):3-11
pubmed: 5942109
Health Aff (Millwood). 1997 May-Jun;16(3):146-50
pubmed: 9141331
Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):841-8
pubmed: 9369132
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):1-9
pubmed: 9747813
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):57-66
pubmed: 9989514